Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9579834 | 0.81 | GABRR1 (0.42) | GABRR1CYP1A2ENPEPLTA4HTP53 | |
| SCHEMBL18099918 | 0.79 | GABRR1 (0.41) | GABRR1CYP1A2ENPEPLTA4HTP53 | |
| SCHEMBL13668753 | 0.79 | ALDH1A1 (0.43) | GABRR1CYP1A2ENPEPLTA4HTP53 | |
| SCHEMBL12257196 | 0.79 | LTA4H (0.55) | GABRR1CYP1A2ENPEPLTA4H | |
| SCHEMBL8948256 | 0.78 | — | — | |
| SCHEMBL26771564 | 0.78 | CHRM1 (0.42) | RNPEPTP53FOLH1 | |
| SCHEMBL10308352 | 0.78 | ALDH1A1 (0.33) | — | |
| SCHEMBL12836151 | 0.78 | ALDH1A1 (0.39) | — | |
| SCHEMBL10806127 | 0.77 | ENPEP (0.44) | GABRR1CYP1A2ENPEPLTA4HRNPEP | |
| SCHEMBL791253 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096446-A1 | Extended Triterpene Derivatives | MYREXIS, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| EP-2385034-B1 | Process for the preparation of 1-nitro-4-oxobutanylamides | SYNKOLA S R O (SK) | 2015-12-02 | — | — | EP | disclosed |
| US-8993607-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8318425-B2 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | The United States of America, as represented by the Secretary, Department & Human Services (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318425-B2 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | The United States of America, as represented by the Secretary, Department & Human Services (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120046234-A1 | THERAPEUTIC COMPOUNDS | NIH - DEITR | 2012-02-23 | — | — | US | disclosed |
| EP-2385034-A2 | Process for the preparation of 1-nitro-4-oxobutanylamides | Synkola, s.r.o. (SK) | 2011-11-09 | — | — | EP | disclosed |
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myriad Pharmaceuticals, Inc.. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100221264-A1 | Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein | PANACOS PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100221264-A1 | Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein | PANACOS PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| CN-101563341-A | Piperidine derivative used for treating chemokine receptor 5 mediated diseases | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | CN | disclosed |
| US-7537765-B2 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | PANACOS PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7537765-B2 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | PANACOS PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080233559-A1 | Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein | PANACOS PHARMACEUTICALS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080200550-A1 | Inhibition of Hiv-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein | V.I. TECHNOLOGIES, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20070197646-A1 | SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197646-A1 | SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-3971816-A | Esters of carboxylic acids formally substituted by sodium or potassium in the alpha-position and the method for their preparation | CESKOSLOVENSKA AKADEMIE VED (CS) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096446-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | GABRR1 1466/4885CYP1A2 708/4885ENPEP 802/4885 |
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | HAVCR2, FURIN, SARS1 | GABRR1 1564/4885CYP1A2 2148/4885ENPEP 36/4885 |
| US-20070197646-A1 | SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS | TARBP1, TSNAX, TARDBP | GABRR1 1841/4885CYP1A2 535/4885ENPEP 2265/4885 |
| US-20120046234-A1 | THERAPEUTIC COMPOUNDS | MKI67, MCL1, TP53 | GABRR1 3789/4885CYP1A2 2396/4885ENPEP 1484/4885 |
| US-20100221264-A1 | Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein | SP1, CPSF1, BET1 | GABRR1 1635/4885CYP1A2 4559/4885ENPEP 419/4885 |
| US-20080200550-A1 | Inhibition of Hiv-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein | SP1, CPSF1, SUB1 | GABRR1 1708/4885CYP1A2 4523/4885ENPEP 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.